Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS improvements, addressing a high unmet need in platinum-resistant ovarian ...

The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...

First and only systemic regimen to demonstrate durable survival benefit in this patient population KEYNOTE-905 marks the fifth study of a KEYTRUDA-based regimen in an earlier stage of cancer to ...